ReviewInfectious diseases and therapy2026
Nucleic Acid-Based Antimicrobial Strategies Against Drug-Resistant Staphylococcus aureus: A Review of Mechanisms of Action and Delivery Approaches.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant Staphylococcus aureus remains one of the major clinical challenges in both community and hospital settings. Increasing rates of resistance to conventional antibiotics have prompted the development of alternative therapeutic strategies capable of selectively targeting essential bacterial functions. Nucleic acid-based antimicrobial strategies have emerged as promising and precise approaches, enabling the inhibition of gene expression, suppression of virulence, restoration of antibiotic susceptibility, and inhibition of bacterial growth in a sequence-specific manner. This review investigates various studies on antisense oligonucleotides (ASOs), small RNA-based approaches, and CRISPR-Cas systems against S. aureus, with a focus on their antimicrobial efficacy, mechanisms of action, and delivery strategies. These platforms can target genes involved in cell division, transcription, quorum sensing, biofilm formation, and antibiotic resistance. As efficient intracellular delivery remains a major barrier, multiple carriers-including cell-penetrating peptides, nanoparticles, liposomes, DNA nanostructures, and phagemid-based platforms-have been developed to enhance therapeutic efficacy. It has been demonstrated that optimized delivery systems can substantially improve the stability, cellular uptake, and antibacterial activity of nucleic acid therapeutics. Furthermore, the programmability and high target specificity of these agents is a step forward, facilitating the development of precision antimicrobial therapies with the potential for reduced effects on non-target bacterial populations. Overall, the available data support the potential of nucleic acid-based antimicrobials as promising preclinical adjuncts to conventional antibiotics for combating multidrug-resistant S. aureus.
Indexed as
Identifiers
42786391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.